These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 332216)

  • 1. Factors influencing antipyrine elimination.
    Stevenson IH
    Br J Clin Pharmacol; 1977 Jun; 4(3):261-5. PubMed ID: 332216
    [No Abstract]   [Full Text] [Related]  

  • 2. Antipyrine kinetics in liver disease and liver transplantation.
    Mehta MU; Venkataramanan R; Burckart GJ; Ptachcinski RJ; Yang SL; Gray JA; Van Thiel DH; Starzl TE
    Clin Pharmacol Ther; 1986 Apr; 39(4):372-7. PubMed ID: 3514052
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of antipyrine kinetics by measurement in saliva.
    Fraser HS; Mucklow JC; Murray S; Davies DS
    Br J Clin Pharmacol; 1976 Apr; 3(2):321-5. PubMed ID: 973966
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Salivary antipyrine half-life: a useful measure of hepatic drug metabolism.
    Brooks PM; Bell MA; Burns H
    Br J Clin Pharmacol; 1976 Oct; 3(5):945-6. PubMed ID: 973995
    [No Abstract]   [Full Text] [Related]  

  • 5. Salivary antipyrine kinetics in hepatic and renal disease and in patients on anticonvulsant therapy.
    Harman AW; Penhall RK; Priestly BG; Frewin DB; Phillips PJ; Clarkson AR
    Aust N Z J Med; 1977 Aug; 7(4):385-90. PubMed ID: 270989
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Saliva and plasma clearance of antipyrine as reflectors of liver function.
    Luoma PV; Sotaniemi EA
    Eur J Drug Metab Pharmacokinet; 1981; 6(4):261-4. PubMed ID: 7333326
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elimination of antipyrine from saliva as a measure of metabolism in man.
    Welch RM; DeAngelis RL; Wingfield M; Farmer TW
    Clin Pharmacol Ther; 1975 Sep; 18(3):249-58. PubMed ID: 1164815
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Iron deficiency anaemia and drug metabolism.
    O'Malley K; Stevenson IH
    J Pharm Pharmacol; 1973 Apr; 25(4):339-40. PubMed ID: 4146690
    [No Abstract]   [Full Text] [Related]  

  • 9. Altered plasma half-lives of antipyrine, propylthiouracil, and methimazole in thyroid dysfunction.
    Vesell ES; Shapiro JR; Passananti T; Jorgensen H; Shively CA
    Clin Pharmacol Ther; 1975 Jan; 17(1):48-56. PubMed ID: 1122669
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impairment of drug elimination in patients with liver disease.
    Narang AP; Datta DV; Mathur VS
    Int J Clin Pharmacol Ther Toxicol; 1985 Jan; 23(1):28-32. PubMed ID: 3988389
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of fever on antipyrine metabolism in children.
    Forsyth JS; Moreland TA; Rylance GW
    Br J Clin Pharmacol; 1982 Jun; 13(6):811-5. PubMed ID: 7093111
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Studies on the disposition of antipyrine, aminopyrine, and phenacetin using plasma, saliva, and urine.
    Vesell ES; Passananti GT; Glenwright PA; Dvorchik BH
    Clin Pharmacol Ther; 1975 Sep; 18(3):259-72. PubMed ID: 1164816
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antipyrine: radioimmunoassay in plasma and saliva following administration of a high dose and a low dose.
    Chang RL; Wood AW; Dixon WR; Conney AH; Anderson KE; Eiseman J; Alvares AP
    Clin Pharmacol Ther; 1976 Aug; 20(2):219-26. PubMed ID: 947654
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Further observations on relationships between antipyrine half-life, clearance and volume of distribution: an appraisal of alternative kinetic parameters used to assess the elimination of antipyrine.
    Sultatos LG; Dvorchik BH; Vesell ES; Shand DG; Branch RA
    Clin Pharmacokinet; 1980; 5(3):263-73. PubMed ID: 7389235
    [No Abstract]   [Full Text] [Related]  

  • 15. Interaction between antipyrine and aminopyrine.
    Vesell ES; Passananti GT; Hepner GW
    Clin Pharmacol Ther; 1976 Dec; 20(6):661-9. PubMed ID: 991537
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antipyrine, paracetamol, and lignocaine elimination in chronic liver disease.
    Forrest JA; Finlayson ND; Adjepon-Yamoah KK; Prescott LF
    Br Med J; 1977 May; 1(6073):1384-7. PubMed ID: 861646
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of drug pretreatment on antipyrine levels in blood and tissues: an example of multiple drug interactions.
    Sotaniemi EA
    Pharmacology; 1973; 10(5):306-16. PubMed ID: 4764537
    [No Abstract]   [Full Text] [Related]  

  • 18. The clearance of antipyrine and indocyanine green in normal subjects and in patients with chronic lever disease.
    Branch RA; James JA; Read AE
    Clin Pharmacol Ther; 1976 Jul; 20(1):81-9. PubMed ID: 1277728
    [TBL] [Abstract][Full Text] [Related]  

  • 19. No impairment of antipyrine elimination by the selective anticholinergic drug pirenzepine.
    Paxton JW; Foote SE; Paton DM
    Digestion; 1983; 27(1):44-6. PubMed ID: 6688400
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Antipyrine test in evaluating the detoxifying function of the liver in chronic diseases].
    Loginov AS; Bendikov EA; Otunbaeva DI; Rykova IA; Petrakov AV
    Ter Arkh; 1982; 54(12):31-4. PubMed ID: 6760440
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.